News | Prostate Cancer | December 22, 2016

Phase II for Development of PSMA-targeted Radionuclide Therapy for Prostate Cancer

Cancer Targeted Technology Commences Second Phase of a $2.3M Contract to Develop an Innovative PSMA-targeted Radionuclide Therapy for Prostate Cancer

 

prostate, CT scan

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute exercised the $2M Phase II option of a Small Business Innovation Research (SBIR) Phase I/II fast-track $2.3M contract to develop a new agent to treat metastatic prostate cancer. The contract develops a promising unique radiotherapeutic drug, CTT1403, that targets Prostate-Specific Membrane Antigen (PSMA). PSMA is over-expressed on prostate cancer and expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s unique phosphoramidate-based agents, bind irreversibly to PSMA and unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells leading to increased accumulation of the therapeutic payload and improved efficacy.

In the Phase I $300K portion of the contract, conducted earlier in 2016, CTT successfully synthesized, tested and identified its lead drug, CTT1403. In addition to the PSMA targeting core, CTT1403 incorporates a chemical motif to increase circulation time, increase tumor uptake and decrease any binding to normal tissues. CTT1403, labeled with lutetium-177, demonstrated excellent circulation times in animal studies and cured 75% of mice implanted with human prostate tumors. CTT is working with Carolyn Anderson, M.D., professor of medicine, at University of Pittsburgh, to evaluate CTT1403 in mouse models of prostate cancer.

Anderson commented: "We are excited to continue our collaboration with CTT. The data from the first phase of the contract are promising, and we look forward to furthering this investigation to translate CTT1403 into human studies.”

The Phase II $2M portion advances CTT1403 into Investigational New Drug (IND) enabling studies, including manufacturing, additional pharmacology and safety assessments. These IND studies will support the initial clinical trial in metastatic prostate cancer. CTT’s strategic plan to identify, target, treat and monitor metastatic prostate cancer, employs CTT1403 as a companion therapeutic agent to CTT’s diagnostic Positron Emission Tomography (PET) agent, CTT1057, that commenced clinical trials in November 2016 to image metastatic sites in patients with prostate cancer.

“We have rationally designed CTT1403 to maximize tumor uptake, while minimizing side effects, and the drug is demonstrating exceptional targeting to prostate tumors in animal models,” stated Beatrice Langton-Webster, Ph.D., CEO of CTT and Principal Investigator on the contract. “We were very excited to see substantial increases in survival times in mice implanted with human prostate tumors. CTT1403 holds great promise as a treatment that will result in meaningful increases in life expectancy for men suffering from prostate cancer.”

For more information: www.cancertargetedtechnology.com/

Related Content

News | Radiopharmaceuticals and Tracers | February 16, 2017
Cerveau Technologies Inc. announced it has signed an agreement with Siemens’ PETNET Solutions Inc. that grants the...
targeted radiosurgery, stereotactic radiosurgery, whole-brain radiation, brain tumor metastases, Cureus, University of Missouri School of Medicine study
News | Radiation Therapy | February 16, 2017
University of Missouri (MU) School of Medicine researchers compared two common postsurgical therapies for metastatic...
ASTRO guideline, bone metastases, pallliative radiation therapy, gold standard
News | Radiation Therapy | February 14, 2017
February 14, 2017 — The American Society for Radiation Oncology (ASTRO) recently published an updated clinical guidel
Accuray, Radixact treatment delivery system, TomoTherapy, Shonin approval, Japan
News | Radiation Therapy | February 13, 2017
February 13, 2017 — Accuray Inc.
ayDCE software, mpMRI, multiparametric magnetic resonance imaging, prostate MRI, RSNA 2017, AHRA, SIIM
Technology | Magnetic Resonance Imaging (MRI) | February 13, 2017
February 13, 2017 —  aycan recently introduced ayDCE software powered by aycan workstation.
state of the proton therapy market entering 2017, proton therapy, radiation therapy, Robust Insight survey
News | Proton Therapy | February 10, 2017
Independent market research consultancy Robust Insight recently conveyed a survey commissioned by IBA on the state of...
EGFR mutant lung cancer, brain metastases, order of treatment, radiation therapy, EGFR-directed drugs, Journal of Clinical Oncology study
News | Lung Cancer | February 09, 2017
February 9, 2017 — A study published in the...
IBA, Dolphin Online Ready Patient QA and Monitoring solution, radiotherapy, North West Cancer Centre, Londonderry, Northern Ireland, first in U.K.
News | Radiation Therapy | February 07, 2017
IBA (Ion Beam Applications S.A.) recently announced the first clinical implementation of its Dolphin Online Ready...
Blue Earth Diagnostics, Axumin, fluciclovine F-18, recurrent prostate cancer, Simens PETNET Solutions, increased patient access
News | Radiopharmaceuticals and Tracers | February 07, 2017
Blue Earth Diagnostics and Siemens’ PETNET Solutions announced that an increasing number of radiopharmacies will offer...
Overlay Init